Bio-Rad Laboratories, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0905722072
USD
320.06
-0.28 (-0.09%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Bio-Rad Laboratories, Inc. stock-summary
stock-summary
Bio-Rad Laboratories, Inc.
Pharmaceuticals & Biotechnology
Bio-Rad Laboratories, Inc. manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Life Science segment markets and develops, manufactures and markets approximately 6,000 reagents, apparatus and laboratory instruments. Its products are used in research techniques, biopharmaceutical production processes and food testing regimes. Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market.
Company Coordinates stock-summary
Company Details
1000 ALFRED NOBEL DR , HERCULES CA : 94547-1811
stock-summary
Tel: 1 510 7247000
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 112 Schemes (49.9%)

Foreign Institutions

Held by 282 Foreign Institutions (21.66%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Norman Schwartz
Chairman of the Board, President, Chief Executive Officer
Mr. Gregory Hinckley
Lead Independent Director
Mrs. Alice Schwartz
Director
Mr. Jeffrey Edwards
Independent Director
Ms. Melinda Litherland
Independent Director
Mr. Arnold Pinkston
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
652 Million
(Quarterly Results - Jun 2025)
Net Profit:
318 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 7,937 Million (Small Cap)

stock-summary
P/E

5.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.02

stock-summary
Return on Equity

6.87%

stock-summary
Price to Book

1.11